239 related articles for article (PubMed ID: 26304152)
1. PAP assays in newborn screening for cystic fibrosis: a population-based cost-effectiveness study.
Seror V; Cao C; Roussey M; Giorgi R
J Med Screen; 2016 Jun; 23(2):62-9. PubMed ID: 26304152
[TBL] [Abstract][Full Text] [Related]
2. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population.
Sommerburg O; Lindner M; Muckenthaler M; Kohlmueller D; Leible S; Feneberg R; Kulozik AE; Mall MA; Hoffmann GF
J Inherit Metab Dis; 2010 Oct; 33(Suppl 2):S263-71. PubMed ID: 20714932
[TBL] [Abstract][Full Text] [Related]
3. A model-based economic evaluation of four newborn screening strategies for cystic fibrosis in Flanders, Belgium.
Schmidt M; Werbrouck A; Verhaeghe N; De Wachter E; Simoens S; Annemans L; Putman K
Acta Clin Belg; 2020 Jun; 75(3):212-220. PubMed ID: 31007159
[No Abstract] [Full Text] [Related]
4. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.
Sarles J; Berthézène P; Le Louarn C; Somma C; Perini JM; Catheline M; Mirallié S; Luzet K; Roussey M; Farriaux JP; Berthelot J; Dagorn JC
J Pediatr; 2005 Sep; 147(3):302-5. PubMed ID: 16182665
[TBL] [Abstract][Full Text] [Related]
5. Five years of experience with biochemical cystic fibrosis newborn screening based on IRT/PAP in Germany.
Sommerburg O; Hammermann J; Lindner M; Stahl M; Muckenthaler M; Kohlmueller D; Happich M; Kulozik AE; Stopsack M; Gahr M; Hoffmann GF; Mall MA
Pediatr Pulmonol; 2015 Jul; 50(7):655-64. PubMed ID: 25914230
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of newborn screening for cystic fibrosis: a simulation study.
Nshimyumukiza L; Bois A; Daigneault P; Lands L; Laberge AM; Fournier D; Duplantie J; Giguère Y; Gekas J; Gagné C; Rousseau F; Reinharz D
J Cyst Fibros; 2014 May; 13(3):267-74. PubMed ID: 24238947
[TBL] [Abstract][Full Text] [Related]
7. Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations.
Sommerburg O; Krulisova V; Hammermann J; Lindner M; Stahl M; Muckenthaler M; Kohlmueller D; Happich M; Kulozik AE; Votava F; Balascakova M; Skalicka V; Stopsack M; Gahr M; Macek M; Mall MA; Hoffmann GF
J Cyst Fibros; 2014 Jan; 13(1):15-23. PubMed ID: 23891278
[TBL] [Abstract][Full Text] [Related]
8. Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA.
Krulišová V; Balaščaková M; Skalická V; Piskáčková T; Holubová A; Paděrová J; Křenková P; Dvořáková L; Zemková D; Kračmar P; Chovancová B; Vávrová V; Stambergová A; Votava F; Macek M
Eur J Pediatr; 2012 Aug; 171(8):1223-9. PubMed ID: 22581207
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of 47,213 infants in neonatal screening for cystic fibrosis, using pancreatitis-associated protein and immunoreactive trypsinogen assays].
Barthellemy S; Maurin N; Roussey M; Férec C; Murolo S; Berthézène P; Iovanna JL; Dagorn JC; Sarles J
Arch Pediatr; 2001 Mar; 8(3):275-81. PubMed ID: 11270251
[TBL] [Abstract][Full Text] [Related]
10. Neonatal screening for cystic fibrosis: comparing the performances of IRT/DNA and IRT/PAP.
Sarles J; Giorgi R; Berthézène P; Munck A; Cheillan D; Dagorn JC; Roussey M
J Cyst Fibros; 2014 Jul; 13(4):384-90. PubMed ID: 24513262
[TBL] [Abstract][Full Text] [Related]
11. Comparison between two newborn screening strategies for cystic fibrosis in Argentina: IRT/IRT versus IRT/PAP.
Teper A; Smithuis F; Rodríguez V; Salvaggio O; Maccallini G; Aranda C; Lubovich S; Zaragoza S; García-Bournissen F
Pediatr Pulmonol; 2021 Jan; 56(1):113-119. PubMed ID: 33095477
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of newborn screening for cystic fibrosis determined with real-life data.
van der Ploeg CP; van den Akker-van Marle ME; Vernooij-van Langen AM; Elvers LH; Gille JJ; Verkerk PH; Dankert-Roelse JE;
J Cyst Fibros; 2015 Mar; 14(2):194-202. PubMed ID: 25213034
[TBL] [Abstract][Full Text] [Related]
13. Blood concentrations of pancreatitis associated protein in neonates: relevance to neonatal screening for cystic fibrosis.
Sarles J; Barthellemy S; Férec C; Iovanna J; Roussey M; Farriaux JP; Toutain A; Berthelot J; Maurin N; Codet JP; Berthézène P; Dagorn JC
Arch Dis Child Fetal Neonatal Ed; 1999 Mar; 80(2):F118-22. PubMed ID: 10325788
[TBL] [Abstract][Full Text] [Related]
14. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study.
Vernooij-van Langen AM; Loeber JG; Elvers B; Triepels RH; Gille JJ; Van der Ploeg CP; Reijntjens S; Dompeling E; Dankert-Roelse JE;
Thorax; 2012 Apr; 67(4):289-95. PubMed ID: 22271776
[TBL] [Abstract][Full Text] [Related]
15. Positive neonatal screening for cystic fibrosis in neonates with renal failure.
Oosterveld MJ; Schilperoort JV; Lilien MR; Arets HG
Thorax; 2010 Jul; 65(7):652-3. PubMed ID: 20627926
[TBL] [Abstract][Full Text] [Related]
16. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
[TBL] [Abstract][Full Text] [Related]
17. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.
Corbetta C; Seia M; Bassotti A; Ambrosioni A; Giunta A; Padoan R
J Med Screen; 2002; 9(2):60-3. PubMed ID: 12133923
[TBL] [Abstract][Full Text] [Related]
18. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
[TBL] [Abstract][Full Text] [Related]
19. A product of immunoreactive trypsinogen and pancreatitis-associated protein as second-tier strategy in cystic fibrosis newborn screening.
Weidler S; Stopsack KH; Hammermann J; Sommerburg O; Mall MA; Hoffmann GF; Kohlmüller D; Okun JG; Macek M; Votava F; Krulišová V; Balaščaková M; Skalická V; Lee-Kirsch MA; Stopsack M
J Cyst Fibros; 2016 Nov; 15(6):752-758. PubMed ID: 27461140
[TBL] [Abstract][Full Text] [Related]
20. Final results of the southwest German pilot study on cystic fibrosis newborn screening - Evaluation of an IRT/PAP protocol with IRT-dependent safety net.
Sommerburg O; Stahl M; Hämmerling S; Gramer G; Muckenthaler MU; Okun J; Kohlmüller D; Happich M; Kulozik AE; Mall MA; Hoffmann GF
J Cyst Fibros; 2022 May; 21(3):422-433. PubMed ID: 34764021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
